RTP Mobile Logo

Interview with Mark Levis, MD, PhD


Track 1: Molecular profiling in the diagnosis and treatment of acute myeloid leukemia (AML)
Track 2: Management of AML with p53 mutations
Track 3: Efficacy of hypomethylating agents with venetoclax in older patients with AML
Track 4: Therapeutic options for patients with AML and FLT3 mutations
Track 5: Monitoring and management of venetoclax-associated tumor lysis syndrome
Track 6: Case: A 62-year-old woman who presents with fatigue and bleeding gums is diagnosed with AML with FLT3 and NPM1 mutations
Track 7: Role of the FLT3 pathway in myeloid cell development and types of FLT3 mutations
Track 8: Impact of FLT3 mutations on therapeutic decision-making
Track 9: Activity of midostaurin in newly diagnosed AML with a FLT3 mutation
Track 10: BMT CTN 1506: A Phase III trial of gilteritinib as maintenance therapy after allogeneic transplant for patients with AML and FLT3-ITD mutations
Track 11: Case: A 60-year-old man with AML and a FLT3-ITD mutation receives gilteritinib with standard 7 + 3 chemotherapy induction followed by allotransplant and maintenance gilteritinib on a clinical trial
Track 12: Similarities and differences among midostaurin, quizartinib and gilteritinib
Track 13: Case: A 63-year-old man with refractory AML and an IDH2 mutation receives enasidenib and develops differentiation syndrome
Track 14: Biologic rationale for targeting IDH1/2 mutations and activity of ivosidenib or enasidenib in patients with relapsed/refractory AML
Track 15: Efficacy and side effects of CPX-351 (liposomal cytarabine/daunorubicin) in patients with AML
Track 16: Case: A 28-year-old obese man with acute lymphoblastic leukemia (ALL) and an MLL rearrangement develops hepatic toxicity after treatment with the Berlin-Frankfurt-Munster pediatric-inspired regimen containing L-asparaginase
Track 17: Mechanism of action, activity and tolerability of blinatumomab for ALL
Track 18: Neurologic side effects associated with blinatumomab
Track 19: Use of blinatumomab for minimal residual disease-positive ALL
Track 20: Optimal use of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive ALL
Track 21: Case: A 41-year-old woman receives chimeric antigen receptor (CAR) T-cell therapy for relapsed ALL
Track 22: Role of CAR T-cell therapy in the management of ALL
Track 23: Use of the antibody-drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin for acute leukemias
Track 24: Activity of gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL)

Interview with Farhad Ravandi, MD

Track 1: Impact of genetic mutations and cytogenetic alterations on prognosis and therapy selection for patients with AML
Track 2: Initial workup for patients with newly diagnosed AML
Track 3: Biologic rationale for, activity of and approval of venetoclax in combination with hypomethylating agents for patients with AML who are 75 or older or have comorbidities
Track 4: Integration of venetoclax with hypomethylating agents into the clinical algorithm for AML
Track 5: Approach to therapy for older patients with AML and FLT3 mutations
Track 6: Management of toxicities associated with venetoclax combined with a hypomethylating agent
Track 7: RATIFY: Results of a Phase III trial evaluating midostaurin with 7 + 3 induction and high-dose cytarabine consolidation and as maintenance therapy for patients with newly diagnosed AML and FLT3 mutations
Track 8: Efficacy of sorafenib, quizartinib or gilteritinib for patients with AML and FLT3 mutations
Track 9: Side effects and spectrum of activity of gilteritinib, quizartinib and midostaurin
Track 10: Case: A 70-year-old man with AML and NPM1 and FLT3 mutations receives azacitidine in combination with venetoclax and sorafenib as third-line therapy
Track 11: Case: A 44-year-old woman with AML and an IDH2 mutation receives enasidenib
Track 12: Perspective on the potential use of enasidenib or ivosidenib in the first-line setting
Track 13: Mechanism of action and efficacy of CPX-351 in patients with therapy-related AML or AML with myelodysplasia-related changes
Track 14: Clinical experience with CPX-351
Track 15: Role of gemtuzumab ozogamicin in the treatment of CD33-positive AML
Track 16: Activity of the recently approved hedgehog inhibitor glasdegib in combination with low-dose cytarabine for newly diagnosed AML in patients aged 75 or older or those with comorbidities
Track 17: Case: A 75-year-old woman with AML and significant comorbidities is enrolled on a clinical trial of decitabine with venetoclax
Track 18: Case: A 76-year-old woman with ALL experiences a complete remission with blinatumomab as second-line therapy
Track 19: Mechanism of action and efficacy of blinatumomab for ALL
Track 20: Activity and tolerability of CAR T-cell therapy for ALL
Track 21: Cytokine release syndrome and neurologic toxicities associated with CAR T-cell therapy and blinatumomab
Track 22: Perspective on the role of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive ALL
Track 23: Efficacy of gemtuzumab ozogamicin in patients with high-risk APL
Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Farhad Ravandi, MD
Janiece and Stephen A Lasher
Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Neil Love, MD
Research To Practice
Miami, Florida